Differential effects of curcumin on vasoactive factors in the diabetic rat heart by Farhangkhoee, Hana et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Nutrition & Metabolism
Open Access Research
Differential effects of curcumin on vasoactive factors in the diabetic 
rat heart
Hana Farhangkhoee1, Zia A Khan1,2, Shali Chen1 and Subrata Chakrabarti*1
Address: 1Department of Pathology, The University of Western Ontario, London, Ontario N6A 5C1, Canada and 2Vascular Biology Program and 
Department of Surgery, Children's Hospital Boston, Harvard Medical School, MA 02115, USA
Email: Hana Farhangkhoee - hfarhang@uwo.ca; Zia A Khan - zia.khan@childrens.harvad.edu; Shali Chen - schen4@uwo.ca; 
Subrata Chakrabarti* - subrata.chakrabarti@schulich.uwo.ca
* Corresponding author    
Abstract
Background: Increased oxidative stress has been associated with the pathogenesis of chronic
diabetic complications, including cardiomyopathy. Recent studies indicate that curcumin, a potent
antioxidant, may be beneficial in preventing diabetes-induced oxidative stress and subsequent
secondary complications. We have investigated the effects of curcumin on the nitric oxide (NO)
pathway in cardiac tissues and cultured cells.
Methods: Streptozotocin-induced diabetic rats were treated with curcumin for a period of one
month. Heart tissues were then analyzed for endothelial NO synthase (eNOS) and inducible NO
synthase (iNOS) mRNA expression. Oxidative protein and DNA damage were assessed by
immunohistochemical analysis of nitrotyrosine and 8-hydroxy-2'-deoxyguanosine (8-OHdG).
Heart tissues were further subjected to endothelin-1 (ET-1) mRNA expression. In order to further
characterize the effects of curcumin, we assayed microvascular endothelial cells (MVECs). Cultured
MVECs, exposed either to glucose or glucose and varying concentrations of curcumin, were
assessed for alterations of NOS expression and activation of nuclear factor-κB (NF-κB) and
activating protein-1 (AP-1). Oxidative stress and ET-1 expression levels were also assayed.
Results: Our results indicate that one month of diabetes causes an upregulation of both eNOS
and iNOS mRNA levels, and nitrotyrosine and 8-OHdG immunoreactivity in the heart. Treatment
of diabetic rats with curcumin reduced eNOS and iNOS levels in association with reduced
oxidative DNA and protein damage. Interestingly, curcumin further increased vasoconstrictor ET-
1 in the heart. Exposure of MVECs to high glucose increased both eNOS and iNOS levels and
oxidative stress. Curcumin prevented NOS alteration and oxidative stress in a dose-dependent
manner which was mediated by nuclear factor-κB and activating protein-1. Exposure to curcumin
also increased ET-1 levels in the MVECs.
Conclusion:  Our studies indicate the differential effects of curcumin in vasoactive factor
expression in the heart and indicate the importance of tissue microenvironment in the treatment
of diabetic complications.
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Background
Nearly 40% of diabetic patients develop secondary com-
plications [1-3]. These complications arise primarily due
to sustained hyperglycemia [4,5]. Among the vast array of
problems associated with long-standing diabetes, cardio-
vascular complications, including diabetic cardiomyopa-
thy, have been clearly documented as detrimental and as
one of the leading causes of mortality [1-3]. Over the
years, research has identified some pathological mecha-
nisms underlying diabetic complications [6-9]. One of the
purposed mechanisms is increased oxidative stress via
augmentation of reactive oxygen species (ROS) [6-9].
An interesting pathway suggested to be involved in aug-
menting oxidative stress is the nitric oxide (NO) pathway
[10,11]. NO is produced by a set of three nitric oxide syn-
thase (NOS) isozymes: endothelial NOS (eNOS), induci-
ble NOS (iNOS), and neuronal NOS (nNOS) [12,13].
These enzymes convert L-arginine to L-citrulline, leading
to the generation of the free radical NO [12,13]. NO is
very reactive and is readily sequestered by superoxide ani-
ons to form peroxynitrite. Peroxynitrite has been shown
to damage proteins by modifying the tyrosine residues
[14,15]. Many studies have shown that eNOS and iNOS
are important players in the pathogenesis of diabetic car-
diovascular complications [8,16-18]. Our previous stud-
ies indicate that diabetes leads to increased eNOS and
iNOS levels in the heart, whereas the amount of NO
remains unaltered [18]. It is plausible that NO is quickly
scavenged by free radicals such as superoxide anions, pro-
ducing peroxynitrite.
Curcumin, the active component in Tumeric Rhizomes
(Curcuma Long Linn), was originally used in tradition
Indian medicine over 3000 years ago [19]. Several studies
have indicated a beneficial role of curcumin in terms of
antioxidant, anti-tumourgenic, and anti-inflammatory
property [20]. A recent study showed that curcumin-
treated diabetic rats had lower blood glucose and glycated
hemoglobin levels, in association with lower oxidative
stress [21]. Furthermore, treatment with curcumin has
been shown to reduce ROS levels in cells isolated from
diabetic patients [22]. It has been suggested that curcumin
may mediate some of the effects by partial inhibition of
iNOS via nuclear factor-κB (NF-κB) [20,23,24]. Hence, we
investigated the role of curcumin on diabetes-induced
vasoactive factor alteration including NO to elucidate the
possible mechanisms underlying the antioxidant activity.
We have further examined the effect of curcumin in cul-
tured endothelial cells.
Methods
Animal model of chronic diabetes
Male Sprague-Dawley rats (Charles River Canada Ltd., QC
Canada), weighing approximately 200–250 g, were ran-
domly divided into three groups (n = 6): controls (CO),
diabetic animals (DM), and diabetic animals treated with
curcumin (DM-C). Diabetes was induced by a single intra-
venous injection of streptozotocin (STZ; 65 mg/kg in cit-
rate buffer, pH = 5.6) [25,26], while the control animals
received the same volume of citrate buffer. The use of STZ
to induce diabetes provides an animal model of type 1
diabetes, as the drug causes β-islet cell apoptosis. Curcu-
min was administered via intraperitoneal injection (150
mg/kg; Sigma-Aldrich, ON Canada) [27,28]. The rats were
monitored daily for ketonuria and were given small doses
of insulin (0.1 – 3 U) to prevent ketosis. After 4 weeks of
treatment, animals were sacrificed and heart tissues were
snap-frozen in liquid nitrogen for gene expression analy-
sis and embedded in paraffin for immunohistochemical
analysis. Clinical monitoring of the animals was also per-
formed to evaluate body weight and blood glucose con-
centrations. All animals were cared for according to the
Guiding Principle in the Care and Use of Animals. All
experiments were approved by the University of Western
Ontario Council on Animal Care Committee.
Endothelial cells cultures
Human microvascular endothelial cells (HMECs; Clonet-
ics, MD USA) were cultured at 2500 cells/cm2 in endothe-
lial growth medium (Clonetics) as previously described
[29]. Cells were culture in 5 mM glucose (low glucose con-
trol; CO) and 25 mM glucose (high glucose; HG). In addi-
tion, cells cultured in HG were treated with varying
concentrations of curcumin (0.1, 10, and 100 µM; HG-C)
[30,31]. After 24 hours of treatment, RNA was extracted
and subjected to Real-time RT-PCR. For subsequent anal-
yses, cells were treated with empirically determined curcu-
min concentration.
RNA extraction and Real Time RT-PCR
RNA was isolated from heart tissues and cultured ECs as
described previously [18,32]. cDNA was synthesized with
3 µg of total RNA. The mRNA levels of eNOS, iNOS, and
ET-1 were quantified using the LightCycler™ (Roche Diag-
nostics Canada, QC Canada) [18,32]. In each reaction
tube the following reagents were added for a final volume
of 20 uL: 10 µL of LC DNA Master SYBR Green 1 (Roche
Diagnostic Canada), 1.6 µL of 25 mM of MgCl2, 1 µL each
of 10 mM forward and reverse primers (Table 1), 5.4 µL of
H2O, and 1µL of cDNA. PCR amplification protocols were
optimized for ideal conditions as described previously
[18,32]. For the assessment of early oxidative stress in cul-
tured ECs [18,29,33], heme oxygenase-1 and -2 (HO-1,
HO-2) were also determined.
Immunohistochemistry
Heart tissues were analyzed for nitrotyrosine, an oxidative
protein damage marker, and 8-Hydrox-2'-deoxy Guanos-
ine (8-OHdG), an oxidative DNA damage marker [18].Nutrition & Metabolism 2006, 3:27 http://www.nutritionandmetabolism.com/content/3/1/27
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Paraffin-embedded heart tissues were sectioned (5 µm)
and transferred to positively charged slides. Slides were
stained using the Vectastain Elite Kit (Vector Laboratories,
ON Canada) and monoclonal antibodies for nitrotyro-
sine (1:100, Caymen Chemicals, MI USA) and 8-OHdG
(1:50, Japan Institute for the Control of Aging, Fukuroi,
Japan). The chromagen, 3'-3' diaminobezine (DAB,
Sigma-Aldrich Canada Ltd) was used to detect the oxida-
tive protein and DNA damage levels. Staining with non-
immune rabbit serum instead of primary antibodies was
used as negative controls. Ten random fields were exam-
ined by two investigators unaware of the experimental
treatment. Nitrotyrosine staining was evaluating by meas-
uring the relative cytoplasmic staining intensity, while 8-
OHdG was assessed by counting the number of positive
cardiomyocytes.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was per-
formed to assess activation of transcription factors, NF-κB
and activating protein-1 (AP-1), as described previously
[29,34].
Statistical analysis
The data are expressed at mean ± S.E.M. and were ana-
lyzed by ANOVA followed by student's t-test. Statistical
differences were considered when p < 0.05.
Results
Clinical monitoring of the diabetic animals
Animals were monitored for body weight gain and blood
glucose levels to assess diabetic dysmetabolism. Diabetic
animals exhibited decreased body weight gain and
increased blood glucose levels as compared to non-dia-
Table 1: Primer sequences and PCR parameters
Gene Primers (5' → 3') Temperature*
Rat eNOS GCAAGACCGATTACACGACA
GTCCTCAGGAGGTCTTGCAC
Denaturation
Annealing
Extension
Signal
95°C-0 sec
57°C-5 sec
72°C-10 sec
85°C-1 sec
Human eNOS [42] CCTCCAGGAAGGAGCAAAC
TCCTGAGAGAGAGGCAAGAGGA
Denaturation
Annealing
Extension
Signal
95°C-0 sec
55°C-5 sec
72°C-8 sec
81°C-1 sec
Rat iNOS ATGGAACAGTATAAGCGAAACACC
GTTTCCGGTCGATGTCATGAGCAAAGG
Denaturation
Annealing
Extension
Signal
95°C-0sec
57°C-5 sec
72°C-10 sec
83°C-1 sec
Human iNOS [42] CCCCATCAAGCCCTTTACTT
CACCTCCTGGTGGTCACTT
Denaturation
Annealing
Extension
Signal
95°C-0 sec
55°C-5 sec
72°C-8 sec
81°C-1 sec
Rat ET-1 GCTCCTGCTCCTCCTTGATG
CTCGCTCTATGTAAGTCATGG
Denaturation
Annealing
Extension
Signal
95°C-0 sec
55°C-5 sec
72°C-20 sec
84°C-1 sec
Human ET-1 AAGCCCTCCAGAGAGCGTTAT
CCGAAGGTCTGTCACCAATGT
6FAM-TGACCCACAACCGAG-MGBNFQ
Denaturation
Annealing
Extension
Signal
95°C-0 sec
55°C-5 sec
72°C-4 sec
72°C-1 sec
Human HO-1 [43] TGATAGAAGAGGCCAAGA
TTTCCAGACAGAGGGACA
Denaturation
Annealing
Extension
Signal
95°C-0 sec
50°C-10 sec
72°C-17 sec
84°C-1 sec
Human HO-2 [43] TGGAGCGCAACAAGGACCAT
CCGGTAGAGCTGCTTGAACT
Denaturation
Annealing
Extension
Signal
95°C-0 sec
50°C-10 sec
72°C-17 sec
84°C-1 sec
β-actin CCTCTATGCCAACACAGTGC
CATCGTACTCCTGCTTGCTG
Denaturation
Annealing
Extension
Signal
95°C-0 sec
58°C-5 sec
72°C-8 sec
83°C-1 sec
* Initial denaturation was carried out at 95 °C for 3 minutes.Nutrition & Metabolism 2006, 3:27 http://www.nutritionandmetabolism.com/content/3/1/27
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betic controls (Table 2). Curcumin did not have any effect
on these parameters.
Diabetes upregulates NOS and ET-1 levels in the heart 
with increased oxidative stress
Heart tissues from diabetic animals exhibited increased
eNOS and iNOS mRNA levels as compared to control rats
(Figure 1A). ET-1 mRNA levels were also increased in the
diabetic animals (Figure 1B). To determine whether alter-
ation of NOS expression was associated with oxidative
stress, we assayed for oxidative protein and DNA damage.
Immunohistochemical analysis showed that diabetes
caused increased nitrotyrosine immunoreactivity (Figure
2A). In addition, heart tissues from diabetic animals
exhibited increased levels of 8-OHdG (Figure 2B).
Curcumin prevents diabetes-induced NOS alteration and 
oxidative damage
Treatment of diabetic animals with curcumin prevented
eNOS and iNOS mRNA upregulation (Figure 1A). Inter-
estingly, curcumin caused a greater increase in diabetes-
induced ET-1 expression in the heart (Figure 1B). We next
determined whether the target organs of diabetic compli-
cations also exhibited increased ET-1 expression upon cur-
cumin treatment. Analysis of retina and kidney samples
revealed that ET-1 was normalized as compared to
untreated diabetic animals (data not shown). The
decrease in eNOS and iNOS levels was associated with
reduced nitrotyrosine staining (Figure 2A), indicating
decreased NO scavenging and oxidative protein damage.
In addition, curcumin-treated diabetic animals showed
decreased oxidative DNA damage (Figure 2B).
Effect of curcumin on high glucose-induced eNOS and 
iNOS expression and oxidative stress in ECs
In order to investigate the mechanisms of curcumin-medi-
ated downregulation of NOS and oxidative stress, we
assayed microvascular ECs. Exposure of ECs to high glu-
cose levels (25 mmol/L) increased both eNOS and iNOS
mRNA levels (Figure 3A). Treatment of cells exposed to 25
mM glucose to varying levels of curcumin prevented both
eNOS and iNOS expression (Figure 3B). Such changes
were mediated by decreased activation of redox-sensitive
transcription factors, NF-κB and AP-1 (Figure 3C and 3D).
To determine whether curcumin alters ET-1 levels in the
ECs, we treated the cells with the maximal concentration
of curcumin (100 µM) and assayed for ET-1 transcript
level by real time RT-PCR. Our results indicate that curcu-
min potentiated high glucose-induced ET-1 levels in the
ECs (Figure 4A).
In order to assess whether curcumin prevents high glu-
cose-induced oxidative stress, we employed the early
molecular marker of oxidative damage, HO-1 and HO-2.
Our results show that glucose-induced HO-1 and HO-2
expression is normalized by pre-treatment with curcumin
(Figure 4B).
Discussion
In the present study, we showed that diabetes causes an
increase in eNOS and iNOS mRNA levels in the cardiac
tissues, in association with increased oxidative protein
and DNA damage. Treatment of diabetic animals with
curcumin prevents diabetes-induced eNOS/iNOS upregu-
lation and oxidative stress. We also report, for the first
time, that curcumin potentiates diabetes-induced ET-1
mRNA levels in the heart. Furthermore, the mechanism of
Effect of curcumin on diabetes-induced vasoactive factor  expression, showing real time RT-PCR analysis of (A) NOS,  and (B) ET-1 transcript levels in the heart tissues [CO, con- trol; DM, diabetics; DM-C, diabetics treated with 150 mg/kg/ d curcumin; *p < 0.05 compared to CO; †p < 0.05 compared  to DM; n = 4/group] Figure 1
Effect of curcumin on diabetes-induced vasoactive factor 
expression, showing real time RT-PCR analysis of (A) NOS, 
and (B) ET-1 transcript levels in the heart tissues [CO, con-
trol; DM, diabetics; DM-C, diabetics treated with 150 mg/kg/
d curcumin; *p < 0.05 compared to CO; †p < 0.05 compared 
to DM; n = 4/group].
Table 2: Clinical monitoring of animals
Treatment Body Weight Gain (gms) Glucose (mM)
CO 510 ± 20 4.2 ± 0.2
DM 435 ± 25* 22.1 ± 2.5*
DM-C 413 ± 2* 19.8 ± 1.4*
* p < 0.05 compared to CONutrition & Metabolism 2006, 3:27 http://www.nutritionandmetabolism.com/content/3/1/27
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NOS alteration by curcumin involves activation of NF-κB
and AP-1.
Over the past several decades, researchers have provided
substantial evidence that oxidative stress is augmented in
diabetic complications, including cardiomyopathy
[35,36]. Several pathways have been shown to augment
oxidative stress during long-standing diabetes [8,9]. The
mechanisms of increased oxidative stress in diabetes are
multifactorial [6-9]. One mechanism is by increasing glu-
cose flux through the aldose reductase pathway, resulting
in alterations of the cofactors required for several impor-
tant antioxidant enzymes. Another mechanisms is an
increased flux through the mitochondrial electron trans-
port chain; thus, leading to the production of a superoxide
anions. Activation of protein kinase C has also been doc-
umented as increasing oxidative stress since such activa-
tion leads to altered NADPH oxidase function. Other
pathways include the generation of advanced glycated end
(AGE) products and glucose auto-oxidation. The NO
pathway has also been implemented in oxidative stress
during diabetic complications [8,9,37]. We have previ-
ously shown that the levels of NO in long-standing diabe-
tes are not changed, however, NOS mRNA expression is
upregulated [18]. This suggests that early increased NO
could be sequestered by scavenger molecules such as
superoxide anions and subsequently damage proteins/
DNA and increase oxidative stress. Our results of the
present study do support this notion. We have shown that
diabetes leads to increased eNOS and iNOS expression in
association with augmented peroxynitrite/8OHdG levels.
Curcumin, a potent antioxidant and anti-inflammatory
compound, has been shown to mediate many biological
affects such as downregulation of NOS [38-40]. A recent
study showed that treating lipopolysaccharide-activated
murine macrophages with curcumin reduced the levels of
iNOS mRNA and protein [39]. The researchers provided
support that the reduction in iNOS was attributed to inhi-
bition of redox-active transcription factors required for
iNOS induction. Curcumin may also directly lead to
reduced NO oxidation by sequestering the reaction inter-
mediate, nitrogen dioxide [41]. Our results confirm these
findings in the heart and show that curcumin reduces NO
scavenging as assessed by lower nitrotyrosine staining lev-
els. We have also shown that both eNOS and iNOS mRNA
levels are reduced in curcumin-treated diabetic cardiac tis-
sues. Moreover, we have provided first evidence of a sim-
ilar effect of curcumin in cultured ECs. These changes were
associated with reduced activation of NF-κB and AP-1.
One other interesting finding of the study is the effect of
curcumin on ET-1 expression in the heart as well as cul-
tured ECs. ET-1 was found to be further increased in cur-
cumin-treated diabetic animals and ECs exposed to high
glucose levels. It is possible that curcumin may have a dif-
ferential effect on the vasoactive factors. Our results show
that curcumin decreases eNOS/iNOS levels in the heart
and cultured ECs but increases ET-1 levels. The mecha-
nism of such action and potential significance remains to
be determined. The differential effects of curcumin on
eNOS/iNOS and ET-1 may be due to the activation of dif-
ferent transcriptional regulators. Another possible expla-
nation may be that the downregulation of eNOS/iNOS
could have a secondary effect on ET-1. It is also plausible
that such an alteration may represent the importance of
Diabetes-induced oxidative stress as assessed by (A) nitroty- rosine, and (B) 8-OHdG staining Figure 2
Diabetes-induced oxidative stress as assessed by (A) nitroty-
rosine, and (B) 8-OHdG staining. Curcumin decreased the 
level of oxidative DNA and protein damage [Original magnifi-
cation X400; *p < 0.05 compared to CO; †p < 0.05 com-
pared to DM].Nutrition & Metabolism 2006, 3:27 http://www.nutritionandmetabolism.com/content/3/1/27
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tissue microenvironment and bystander cells. In support
of such a notion, our studies indicate that curcumin
decreases ET-1 levels in the kidneys and the retina (data
not shown). Further studies are necessary to elucidate
whether such differences represent the different molecular
aberrations in the target organs of chronic diabetic com-
plications.
Conclusion
Our results support the findings that curcumin prevents
diabetes-induced oxidative protein and DNA damage, in
association with decreasing NOS levels. Our findings also
suggest that the use of curcumin in novel therapeutic
modalities should be approached with caution, as curcu-
min may augment vasoactive peptide ET-1 and lead to
vascular dysfunction in diabetes.
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Effect of high glucose levels (A) and curcumin (B) on NOS mRNA levels and transcription factor activity in ECs Figure 3
Effect of high glucose levels (A) and curcumin (B) on NOS mRNA levels and transcription factor activity in ECs. ECs exposed 
to 25 mM glucose were treated with varying curcumin concentrations (0.1, 10, and 100 µM in B) and assayed for eNOS and 
iNOS expression (A and B) and transcription factor activity (C and D) [CO, 5 mM glucose; HG, 25 mM glucose; HG-C, HG + 
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